Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat
Moderna (NASDAQ: MRNA) reported Q3 EPS of ($0.59), $0.16 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $157.91 million versus the consensus estimate of $77.51 million.
“The Moderna team continued to execute on our plan in the third quarter. We now have four programs in Phase 2 studies, in addition to the Phase 3 study of our COVID-19 vaccine, mRNA-1273, which is fully enrolled. Our CMV vaccine showed positive interim Phase 2 data and we are now preparing for the Phase 3 start in 2021. We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world. Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I believe that if we launch our COVID-19 vaccine, 2021 could be the most important inflection year in Moderna’s history. We will have the resources to scale Moderna to maximize the impact we can have on patients in the next 10 years through numerous new medicines.”
For earnings history and earnings-related data on Moderna (MRNA) click here.